english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Empagliflozin (Jardiance°) in chronic heart failure

  Marketing Authorisations  Given the absence of any comparison with other heart-failure drugs, empagliflozin has not been shown to represent a therapeutic advance. In particular, when the left ventricular ejection fraction is reduced, there is no evidence to suggest that empagliflozin offers any advantages over dapagliflozin.
Full article (2 pages) available for download by subscribers
1 March 2023

Winners and losers

  Marketing Authorisations  In the European Union, it has been possible since the mid-2000s for a drug's marketing authorisation to be conditional, i.e. granted on condition that the company subsequently provides data to justify full, standard marketing authorisation. The stated aim is commendable: hasten access to a drug in situations where no satisfactory options are available to patients and healthcare professionals.
Full article (1 page) available for download by subscribers
1 March 2023

Building the evidence base

 Editorial  Healthcare decisions are based on the available evaluation data, also referred to as "evidence". This evidence base is constantly evolving, through a process of continuous construction and reconstruction. We can all play our part, in our own way, in building and improving the evidence base.
1 February 2023

Semaglutide (Wegovy°) for excess body weight: nothing new

  Marketing Authorisations  While awaiting publication of the full, detailed results of the "Select" trial, it is best not to count on semaglutide to achieve durable weight loss, but to focus instead on a comprehensive non-pharmacological approach.
Full article (3 pages) available for download by subscribers
1 February 2023

Icosapent ethyl (Vazkepa°) in cardiovascular prevention: not acceptable

  Marketing Authorisations  Despite trials including tens of thousands of patients, omega-3 fatty acids have not been shown to improve clinical outcomes in cardiovascular prevention. The evaluation data on icosapent ethyl, which is simply a source of the omega-3 fatty acid eicosapentaenoic acid, do not alter this conclusion.
Full article (3 pages) available for download by subscribers
1 February 2023

Metformin during pregnancy: possible risk of malformations

 Adverse Effects  Metformin does not appear to be associated with a high risk of malformations, but the available data do not rule out the possibility that metformin exposure increases the risk of certain rare but serious malformations.
Full article (3 pages) available for download by subscribers
1 February 2023

Drugs to avoid in the name of better patient care: 2023 update

Drugs to avoid  DRUGS TO AVOID - 2023 UPDATE  To make it easier to choose quality care, and to prevent disproportionate harm to patients, Prescrire has published its annual update of drugs to avoid. Learn more...
Full article (11 pages) available for free download
1 February 2023

Universities challenge the impact factor

At the start of the 2020s, steps are being taken in some countries to improve the assessment of research.
1 February 2023

Covid-19: Follow Prescrire's independent, evidence-based analysis of the pandemic

 COVID-19  Prescrire's editors are publishing an ongoing series of articles featuring independent analysis of developments related to the covid-19 pandemic. Useful and practical information, to help health professionals gain a clear and balanced view.
1 June 2023

Revolving door between the public and private sectors: conflict of interest

 Editorial  In Europe, as in the United States, senior public officials sometimes go on to occupy positions in the private, for-profit sector, and vice versa. The blurring of roles and conflicts of interest this situation engenders are detrimental to the public interest. There are many such examples in the health sector.
1 January 2023

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90